<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696540</url>
  </required_header>
  <id_info>
    <org_study_id>UDP-CT1-08</org_study_id>
    <nct_id>NCT00696540</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline for Outpatient Bronchiolitis</brief_title>
  <acronym>Hypertonic</acronym>
  <official_title>Safety and Efficacy of Hypertonic Vrs. Normal Saline as Diluent of Salbutamol to Reduce Respiratory Distress in Outpatients With the Clinical Diagnosis of Bronchiolitis During the RSV Epidemic.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Diego Portales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clínica Vespucio, Santiago, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Diego Portales</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will study if small children who become ill with respiratory distress during the RSV
      epidemic are better relieved with salbutamol nebulizations diluted in hypertonic (3%),
      instead of normal (0.9%) saline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Santiago, Chile, a near collapse of health services is a notorious feature of every winter
      when vast numbers of small children line for attention because of respiratory distress caused
      by a probable RSV infection.

      Our study will examine if nebulized salbutamol diluted in hypertonic (3%), instead of normal
      (0.9%) saline, provides better relief in outpatients.

      If hypertonic saline proves safe and effective, the patients could be better managed and the
      pressure for attention diminished at a low cost, by a simple change in the saline ampule.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">October 2008</completion_date>
  <primary_completion_date type="Anticipated">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the respiratory distress score (Tal) between the basal score and the final score after 3 salbutamol nebulizations</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the respiratory distress score (Tal) between the basal score and the first nebulization</measure>
    <time_frame>15 to 20 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the respiratory distress score (Tal) between the basal score and the second nebulization</measure>
    <time_frame>15 to 20 minutes after the first nebulization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse oxymetry reading between the basal score and after each of the three nebulizations</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac frequency, irritability, general condition or anything else between the basal score and the first, second and third nebulization</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Bronchiolitis</condition>
  <condition>Respiratory Distress</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol is diluted in hypertonic (3%) saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salbutamol is diluted in normal (0.9%) saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhalation of salbutamol diluted in hypertonic saline</intervention_name>
    <description>The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Albuterol diluted in hypertonic saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhalation of salbutamol diluted in normal saline</intervention_name>
    <description>The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Albuterol diluted in normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 1 to 24 months

          2. Mild to moderate respiratory distress (Tal score below 9)

          3. Up to 5 days of respiratory symptoms, including today

          4. Expiratory wheezing heard on chest auscultation

          5. Indication of salbutamol nebulization treatment by attending physician

        Exclusion Criteria:

          1. Two prior episodes of wheezing

          2. Premature birth (below 38 weeks), if below 6 months of age

          3. Lobar pneumonia

          4. Body temperature above 38 degree Celsius

          5. Use of salbutamol during the previous 6 hours

          6. Pulse oxymetry reading below 90%

          7. Congenital heart disease

          8. Chronic pulmonary disease: Asthma, cystic fibrosis, bronchopulmonary dysplasia

          9. Other chronic or genetic condition or disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irmeli Roine, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Diego Portales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Mercado, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Vespucio, Santiago, Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irmeli Roine, MD, PhD</last_name>
    <phone>+56-2-6762916</phone>
    <email>irmeli.roine@prof.udp.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo Mercado, MD</last_name>
    <phone>+56-9-3320792</phone>
    <email>rmercado@ssmso.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clínica Vespucio</name>
      <address>
        <city>Santiago</city>
        <zip>00300</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Mercado, MD</last_name>
      <phone>+56-2-8206500</phone>
      <email>rmercado@ssmso.cl</email>
    </contact>
    <contact_backup>
      <last_name>Patricio Olivares, MD</last_name>
      <phone>+56-2-8206500</phone>
      <email>patovares@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Sarrell EM, Tal G, Witzling M, Someck E, Houri S, Cohen HA, Mandelberg A. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest. 2002 Dec;122(6):2015-20.</citation>
    <PMID>12475841</PMID>
  </reference>
  <reference>
    <citation>Mandelberg A, Tal G, Witzling M, Someck E, Houri S, Balin A, Priel IE. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest. 2003 Feb;123(2):481-7.</citation>
    <PMID>12576370</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <last_update_submitted>June 9, 2008</last_update_submitted>
  <last_update_submitted_qc>June 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Irmeli Roine</name_title>
    <organization>Facultad de Ciencias de la Salud, Universidad Diego Portales, Santiago. Chile</organization>
  </responsible_party>
  <keyword>Bronchiolitis, respiratory distress, hypertonic saline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

